Cargando…

Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study

Recent studies have shown that sodium–glucose cotransporter 2 inhibitors decrease the risk of heart failure in patients with type 2 diabetes. However, the precise mechanisms of action of these drugs are not well understood. In the present study, we evaluated the effect of treatment with tofogliflozi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tochiya, Mayu, Makino, Hisashi, Tamanaha, Tamiko, Matsuo, Miki, Hishida, Ai, Koezuka, Ryo, Ohata, Yoko, Tomita, Tsutomu, Son, Choel, Miyamoto, Yoshihiro, Yasuda, Satoshi, Hosoda, Kiminori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078080/ https://www.ncbi.nlm.nih.gov/pubmed/31361403 http://dx.doi.org/10.1111/jdi.13122

Ejemplares similares

Diabetic microvascular complications predicts non‐heart failure with reduced ejection fraction in type 2 diabetes
por: Tochiya, Mayu, et al.
Publicado: (2023)

Efficacy of visceral fat estimation by dual bioelectrical impedance analysis in detecting cardiovascular risk factors in patients with type 2 diabetes
por: Omura-Ohata, Yoko, et al.
Publicado: (2019)

A Prospective Longitudinal Study on the Relationship Between Glucose Fluctuation and Cognitive Function in Type 2 Diabetes: PROPOSAL Study Protocol
por: Matsubara, Masaki, et al.
Publicado: (2020)

Intensity of statin therapy and new hospitalizations for heart failure in patients with type 2 diabetes
por: Kishimoto, Ichiro, et al.
Publicado: (2015)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

First Case Report of Arrhythmogenic Right Ventricular Cardiomyopathy Showing Refractory Ventricular Tachycardia Induced by Thyroid Storm due to Graves' Disease
por: Matsubara, Masaki, et al.
Publicado: (2022)

Adipocyte-specific expression of C-type natriuretic peptide suppresses lipid metabolism and adipocyte hypertrophy in adipose tissues in mice fed high-fat diet
por: Bae, Cho-Rong, et al.
Publicado: (2018)

Overexpression of C-type Natriuretic Peptide in Endothelial Cells Protects against Insulin Resistance and Inflammation during Diet-induced Obesity
por: Bae, Cho-Rong, et al.
Publicado: (2017)

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
por: Suzuki, Katsunori, et al.
Publicado: (2016)

Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

The G-Protein-Coupled Long-Chain Fatty Acid Receptor GPR40 and Glucose Metabolism
por: Tomita, Tsutomu, et al.
Publicado: (2014)

Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus
por: Higashikawa, Toshihiro, et al.
Publicado: (2020)

The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus
por: Katakami, Naoto, et al.
Publicado: (2021)

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
por: Matsuba, Ren, et al.
Publicado: (2018)

Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Association between Achilles Tendon Softness and Atherosclerotic Cardiovascular Disease in Patients with Familial Hypercholesterolemia
por: Michikura, Masahito, et al.
Publicado: (2022)

Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial
por: Son, Cheol, et al.
Publicado: (2019)

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
por: Yoneda, Masato, et al.
Publicado: (2022)

Longitudinal Trajectories of Fasting Plasma Glucose and Risks of Cardiovascular Diseases in Middle Age to Elderly People Within the General Japanese Population: The Suita Study
por: Ogata, Soshiro, et al.
Publicado: (2019)

Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus
por: Kamei, Shinji, et al.
Publicado: (2018)

Gender Differences in Cardiac Function Following Three-Month Administration of Tofogliflozin in Patients With Diabetes Mellitus
por: Higashikawa, Toshihiro, et al.
Publicado: (2020)

Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall—a sub-analysis of the UTOPIA trial
por: Katakami, Naoto, et al.
Publicado: (2022)

Effectiveness of nationwide screening and lifestyle intervention for abdominal obesity and cardiometabolic risks in Japan: The metabolic syndrome and comprehensive lifestyle intervention study on nationwide database in Japan (MetS ACTION-J study)
por: Nakao, Yoko M., et al.
Publicado: (2018)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
por: Ouchi, Motoshi, et al.
Publicado: (2018)

Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction
por: Ito, Shiori, et al.
Publicado: (2018)

Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance
por: Nojima, T., et al.
Publicado: (2020)

Outcome Prediction in Acute Stroke Patients by Continuous Glucose Monitoring
por: Wada, Shinichi, et al.
Publicado: (2018)

Glucose Fluctuation and Severe Internal Carotid Artery Siphon Stenosis in Type 2 Diabetes Patients
por: Eto, Futoshi, et al.
Publicado: (2021)

Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
por: Nunoi, Kiyohide, et al.
Publicado: (2019)

Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study
por: Katakami, Naoto, et al.
Publicado: (2020)

Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
por: Hirose, Sachie, et al.
Publicado: (2016)

Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice
por: Obara, Koki, et al.
Publicado: (2017)

The effects of 12-month administration of tofogliflozin on electrolytes and dehydration in mainly elderly Japanese patients with type 2 diabetes mellitus
por: Higashikawa, Toshihiro, et al.
Publicado: (2018)

Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes
por: Nunoi, Kiyohide, et al.
Publicado: (2018)

The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study
por: Kakuda, Hirokazu, et al.
Publicado: (2017)

Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring
por: Kawaguchi, Yuji, et al.
Publicado: (2020)

The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
por: Li, Zi, et al.
Publicado: (2020)

The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice
por: Hanaguri, Junya, et al.
Publicado: (2022)

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus
por: Nomura, Shosaku, et al.
Publicado: (2023)

Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial
por: Katakami, Naoto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_atc2d6ekdr2g4s860cqke7d60s